Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean of oman o[au] (2 results)?
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.
Naranbhai V, Nathan A, Kaseke C, Berrios C, Khatri A, Choi S, Getz MA, Tano-Menka R, Ofoman O, Gayton A, Senjobe F, Zhao Z, St Denis KJ, Lam EC, Carrington M, Garcia-Beltran WF, Balazs AB, Walker BD, Iafrate AJ, Gaiha GD. Naranbhai V, et al. Among authors: ofoman o. Cell. 2022 Mar 17;185(6):1041-1051.e6. doi: 10.1016/j.cell.2022.01.029. Epub 2022 Feb 3. Cell. 2022. PMID: 35202566 Free PMC article.
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, Feldman J, Roederer AL, Gregory DJ, Poznansky MC, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB. Garcia-Beltran WF, et al. Among authors: ofoman o. Cell. 2022 Feb 3;185(3):457-466.e4. doi: 10.1016/j.cell.2021.12.033. Epub 2022 Jan 6. Cell. 2022. PMID: 34995482 Free PMC article.
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.
Naranbhai V, Nathan A, Kaseke C, Berrios C, Khatri A, Choi S, Getz MA, Tano-Menka R, Ofoman O, Gayton A, Senjobe F, Zhao Z, St Denis KJ, Lam EC, Carrington M, Garcia-Beltran WF, Balazs AB, Walker BD, Iafrate AJ, Gaiha GD. Naranbhai V, et al. Among authors: ofoman o. Cell. 2022 Mar 31;185(7):1259. doi: 10.1016/j.cell.2022.03.022. Cell. 2022. PMID: 35364034 Free PMC article. No abstract available.
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.
Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF. Naranbhai V, et al. Among authors: ofoman o. J Clin Oncol. 2022 Jan 1;40(1):12-23. doi: 10.1200/JCO.21.01891. Epub 2021 Nov 9. J Clin Oncol. 2022. PMID: 34752147 Free PMC article.
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, Feldman J, Gregory DJ, Poznansky MC, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB. Garcia-Beltran WF, et al. Among authors: ofoman o. medRxiv [Preprint]. 2021 Dec 14:2021.12.14.21267755. doi: 10.1101/2021.12.14.21267755. medRxiv. 2021. PMID: 34931201 Free PMC article. Updated. Preprint.
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals.
Naranbhai V, Nathan A, Kaseke C, Berrios C, Khatri A, Choi S, Getz MA, Tano-Menka R, Ofoman O, Gayton A, Senjobe F, Denis KJS, Lam EC, Garcia-Beltran WF, Balazs AB, Walker BD, Iafrate AJ, Gaiha GD. Naranbhai V, et al. Among authors: ofoman o. medRxiv [Preprint]. 2022 Jan 5:2022.01.04.21268586. doi: 10.1101/2022.01.04.21268586. medRxiv. 2022. PMID: 35018386 Free PMC article. Updated. Preprint.
Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency.
Barmettler S, DiGiacomo DV, Yang NJ, Lam T, Naranbhai V, Dighe AS, Burke KE, Blumenthal KG, Ling M, Hesterberg PE, Saff RR, MacLean J, Ofoman O, Berrios C, St Denis KJ, Lam EC, Gregory D, Iafrate AJ, Poznansky M, Lee H, Balazs A, Pillai S, Farmer JR. Barmettler S, et al. Among authors: ofoman o. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1622-1634.e4. doi: 10.1016/j.jaip.2022.03.017. Epub 2022 Apr 2. J Allergy Clin Immunol Pract. 2022. PMID: 35381395 Free PMC article.